Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
نویسندگان
چکیده
منابع مشابه
Severe skin reaction secondary to concomitant radiotherapy plus cetuximab
The therapeutic use of monoclonal antibodies against the epidermal growth factor receptor (EGFR) is specifically associated with dermatologic reactions of variable severity. Recent evidence suggests superiority of the EGFR inhibitor (EGFRI) cetuximab plus radiotherapy compared to radiotherapy alone in patients with squamous cell carcinoma of the head and neck. Although not documented in a study...
متن کاملLow peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment.
Malignant glioma patients treated with the golden standard therapy, focal radiotherapy plus concomitant daily temozolomide (radiotherapy/TMZ), often suffer severe lymphopenia. The frequency of severe lymphopenia and its predictors were analyzed by assessing adverse effects including decrease in white blood cell counts, lymphocyte counts, and neutrocyte counts according to the Common Toxicity Cr...
متن کاملEstimation of Secondary Skin Cancer Risk Due To Electron Contamination in 18-MV LINAC-Based Prostate Radiotherapy
Introduction Accurate estimation of the skin-absorbed dose in external radiation therapy is essential to estimating the probability of secondary carcinogenesis induction Materials and Methods Electron contamination in prostate radiotherapy was investigated using the Monte Carlo (MC) code calculation. In addition, field size dependence of the skin dose was assessed. Excess cancer risk induced by...
متن کاملInitial experience of radiotherapy plus cetuximab for Japanese head and neck cancer patients
In Japan, cetuximab with concurrent bioradiotherapy (BRT) for squamous cell carcinoma of head and neck (SCCHN) was approved in December 2012. We herein report our initial experience of BRT, with special emphasis on acute toxicities of this combination therapy. Thirty-one non-metastatic SCCHN patients who underwent BRT using cetuximab between July 2013 and June 2014 were retrospectively evaluate...
متن کاملRadiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
BACKGROUND We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a monoclonal antibody against the epidermal growth factor receptor, in the treatment of locoregionally advanced squamous-cell carcinoma of the head and neck. METHODS Patients with locoregionally advanced head and neck cancer were randomly assigned to treatment with high-do...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Radiation Oncology
سال: 2008
ISSN: 1748-717X
DOI: 10.1186/1748-717x-3-5